The wheezo device. Source: Respiri
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • King’s College, London (KCL) receives a National Institute for Health Research (NIHR) funded UK paediatric asthma clinical trial using Respiri’s (RSH) wheezo device
  • The £2 million trial will assess the impact of the device when combined with a standard integrated care approach for asthma, for their effectiveness and cost-utility
  • Respiri CEO and Managing Director Marjan Mikel believes the trial will show positive health outcomes for asthmatics and lower the cost burden for government-funded health systems
  • The Technology Enhanced Integrated Asthma care trial is expected to commence in Q4 2022, with results expected by the end of 2023 and interim data available for analysis as the trial progresses
  • Shares in Respiri end the day 1.96 per cent in the red to close at five cents

King’s College, London (KCL) has been awarded a National Institute for Health Research (NIHR) funded UK paediatric asthma clinical trial using Respiri’s (RSH) wheezo device.

The wheezo device is used to monitor and manage the symptoms of asthma, and provides asthma management features as well as information about symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them.

The £2 million trial will assess the impact of the wheezo device when combined with a standard integrated care approach for asthma, for their effectiveness and cost-utility.

Both investigators picked wheezo as the preferred intervention for remote asthma monitoring.

Respiri CEO and Managing Director Marjan Mikel believes the trial will show positive health outcomes for asthmatics and lower the cost burden for government-funded health systems.

“It’s pleasing to finally see that asthmatics can also reap the benefits of new technologies just like other chronic disease sufferers and we are now at an exciting phase to deliver this with this clinical trial,” he said.

“Not only is this the NIHR funded study a great vindication of the wheezo device but it also provides a funded study that enables Respiri to accelerate the process to get this new technology into patient hands faster.”

The Technology Enhanced Integrated Asthma care (TEAM-care) trial is a three-arm, randomised, 30-month, 1464-patient clinical trial that aims to assess outcomes for children with asthma using a technologically enhanced integrated care pathway.

The pathway is said to address an unmet clinical need by building the clinical and health economic evidence base for NHS adoption of new technologies for asthma self-management, treatment optimisation, and monitoring.

The trial is expected to commence in Q4 2022, with results expected by the end of 2023 and interim data available for analysis as the trial progresses.

Shares in Respiri ended the day 1.96 per cent in the red to close at five cents.

RSH by the numbers
More From The Market Herald
The Market Herald Video

" Woomera Mining (ASX:WML) appoints Jason Livingstone as new Managing Director

Mineral explorer Woomera Mining (ASX:WML) has appointed Jason Livingstone as its new Managing Director, effective from…
The Market Herald Video

" Security Matters (ASX:SMX) enters into $2m standby equity facility

Security Matters (ASX:SMX) has entered into a standby equity deed with Evolution Capital.
The Market Herald Video

" Ora Gold (ASX:OAU) obtains unsecured $500k loan facility

Ora Gold (ASX:OAU) has obtained an unsecured $500,000 loan facility from Ioma to assist with general…
Baby Bunting (ASX:BBN) - Chair and Non Executive Director, Melanie Wilson

" Baby Bunting (ASX:BBN) surpasses $500m sales for the first time

Baby goods retailer Baby Bunting (ASX:BBN) surpasses half a billion dollars in sales for the first…